Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Pegunigalsidase alfa

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Chiesi, Protalix Get CHMP Nod For Elfabrio 4-Week Dosing In EU
    Chiesi, Protalix Get CHMP Nod For Elfabrio 4-Week Dosing In EU

    30 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/30/3229591/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-BioTherapeutics-Receive-Positive-CHMP-Opinion-for-an-Additional-Dosing-Regimen-of-Every-Four-Weeks-for-Elfabrio-pegunigalsidase-alfa-in-the.html

    GLOBENEWSWIRE
    30 Jan 2026
    Share Share
    Chiesi Global Rare Diseases Receives Canada Approval of Elfabrio
    Chiesi Global Rare Diseases Receives Canada Approval of Elfabrio

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206235/0/en/Chiesi-Global-Rare-Diseases-Announces-Health-Canada-Approval-of-Elfabrio-pegunigalsidase-alfa-for-Fabry-Disease.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Chiesi Farmaceutici`s Elfabrio Approved in Canada
    Chiesi Farmaceutici`s Elfabrio Approved in Canada

    09 Dec 2025

    // HEALTH CANADA

    https://pdf.hres.ca/dpd_pm/00082715.PDF

    HEALTH CANADA
    09 Dec 2025
    Share Share
    Chiesi, Protalix Seek EMA Re-Exam for Elfabrio 4-Week Dosing
    Chiesi, Protalix Seek EMA Re-Exam for Elfabrio 4-Week Dosing

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179856/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-BioTherapeutics-Seek-Re-examination-from-the-EMA-for-the-Negative-Opinion-for-Elfabrio-pegunigalsidase-alfa-Alternative-Dosing-Regimen-of-E.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
    NICE recommends Chiesi’s Elfabrio for adults with Fabry disease

    05 Sep 2023

    // PM LIVE

    https://www.pmlive.com/pharma_news/nice_recommends_chiesis_elfabrio_for_adults_with_fabry_disease_1497865

    PM LIVE
    05 Sep 2023
    Share Share
    Chiesi Farmaceutici's Elfabrio (Pegunigalsidase alfa) Receives Approval in the Europe
    Chiesi Farmaceutici's Elfabrio (Pegunigalsidase alfa) Receives Approval in the Europe

    25 May 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/elfabrio-epar-medicine-overview_en.pdf

    EMA
    25 May 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.